Advertisement
UK markets close in 7 hours 55 minutes
  • FTSE 100

    8,080.54
    +40.16 (+0.50%)
     
  • FTSE 250

    19,621.04
    -98.33 (-0.50%)
     
  • AIM

    754.12
    -0.57 (-0.08%)
     
  • GBP/EUR

    1.1661
    +0.0016 (+0.14%)
     
  • GBP/USD

    1.2500
    +0.0038 (+0.30%)
     
  • Bitcoin GBP

    51,400.84
    -2,008.10 (-3.76%)
     
  • CMC Crypto 200

    1,391.35
    +8.78 (+0.63%)
     
  • S&P 500

    5,071.63
    +1.08 (+0.02%)
     
  • DOW

    38,460.92
    -42.77 (-0.11%)
     
  • CRUDE OIL

    82.97
    +0.16 (+0.19%)
     
  • GOLD FUTURES

    2,334.30
    -4.10 (-0.18%)
     
  • NIKKEI 225

    37,628.48
    -831.60 (-2.16%)
     
  • HANG SENG

    17,285.95
    +84.68 (+0.49%)
     
  • DAX

    18,002.69
    -86.01 (-0.48%)
     
  • CAC 40

    8,072.30
    -19.56 (-0.24%)
     

Sirius XM Earnings, Revenue Beat in Q2

Sirius XM Earnings, Revenue Beat in Q2
Sirius XM Earnings, Revenue Beat in Q2

Investing.com - Sirius XM (NASDAQ:SIRI) reported second quarter earnings that beat analysts' expectations on Tuesday and revenue that topped forecasts.

The firm reported earnings per share of $0.06 on revenue of $1.98B. Analysts polled by Investing.com anticipated EPS of $0.05 on revenue of $1.93B. That compared to EPS of $0.06 on revenue of $1.43B in the same period a year earlier. The company had reported EPS of $0.03 on revenue of $1.86B in the previous quarter.

Sirius XM follows other major Services sector earnings this month


On Thursday, Amazon.com reported second quarter EPS of $5.22 on revenue of $63.4B, compared to forecasts of EPS of $5.56 on revenue of $62.52B.

ADVERTISEMENT

Visa A earnings beat analysts' expectations on July 24, with third quarter EPS of $1.37 on revenue of $5.84B. Investing.com analysts expected EPS of $1.32 on revenue of $5.7B

Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar

Related Articles

Celgene Earnings Miss, Revenue Beats In Q2

Eli Lilly tops revenue estimates on diabetes drug boost

Karmic reckoning? Investors in activist hedge funds agitate for change